William G. Wierda, MD, PhD
Patients with chronic lymphocytic leukemia (CLL) who stopped treatment with ibrutinib for toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation (RT), as reported in a study published in the journal Cancer
“The development of effective salvage strategies for patients who develop progression/RT while receiving ibrutinib therapy is of critical importance,” the researchers wrote. “Ideally, these strategies should be guided by knowledge of the molecular mechanisms of resistance in an individual patient. Several molecular mutations associated with ibrutinib resistance have been identified, but whether these specifically predict for response to subsequent salvage therapy is unclear and should be systematically studied in the future.”
- Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib [published online February 7, 2017]. Cancer. doi: 10.1002/cncr.30596.
- Jain N, Basu S, Thompson PA, et al. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial. 58th ASH Annual Meeting and Exposition; San Diego, California; December 2-6, 2016. Abstract 59.
... to read the full story